1
|
Sharoyko VV, Mikolaichuk OV, Shemchuk OS, O. E. Abdelhali A, Potanin AA, Luttsev MD, Dadadzanov DR, Vartanyan TA, Petrov AV, Yu. Shasherina A, Murin IV, Maystrenko DN, Molchanov OE, Semenov KN. Novel non-covalent conjugate based on graphene oxide and alkylating agent from 1,3,5-triazine class. J Mol Liq 2023. [DOI: 10.1016/j.molliq.2023.121203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
2
|
Nanomedicines Bearing an Alkylating Cytostatic Drug from the Group of 1,3,5-Triazine Derivatives: Development and Characterization. Pharmaceutics 2022; 14:pharmaceutics14112506. [PMID: 36432699 PMCID: PMC9694467 DOI: 10.3390/pharmaceutics14112506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 11/15/2022] [Accepted: 11/16/2022] [Indexed: 11/22/2022] Open
Abstract
Cancer is still one of the major diseases worldwide. The discovery of new drugs and the improvement of existing ones is one of the areas of priority in the fight against cancer. Dioxadet ([5-[[4,6-bis(aziridin-1-yl)-1,3,5-triazin-2-yl]amino]-2,2-dimethyl-1,3-dioxan-5-yl]methanol) represents one of the promising 1,3,5-triazine derivatives and has cytostatic activity towards ovarian cancer. In this study, we first report the development of dioxadet-bearing nanomedicines based on block-copolymers of poly(ethylene glycol) monomethyl ether (mPEG) and poly(D,L-lactic acid) (PLA)/poly(ε-caprolactone) (PCL) and then conduct an investigation into their characteristics and properties. The preparation of narrow-sized nanoparticles with a hydrodynamic diameter of 100−120 nm was optimized using a nanoprecipitation approach. Thoughtful optimization of the preparation of nanomedicines was carried out through adjustments to the polymer’s molecular weight, the pH of the aqueous medium used for nanoprecipitation, the initial drug amount in respect to the polymer, and polymer concentration in the organic phase. Under optimized conditions, spherical-shaped nanomedicines with a hydrodynamic diameter of up to 230 nm (PDI < 0.2) containing up to 592 ± 22 μg of dioxadet per mg of polymer nanoparticles were prepared. Study of the drug’s release in a model medium revealed the release up to 64% and 46% of the drug after 8 days for mPEG-b-PLA and mPEG-b-PCL, respectively. Deep analysis of the release mechanisms was carried out with the use of a number of mathematical models. The developed nanoparticles were non-toxic towards both normal (CHO-K1) and cancer (A2780 and SK-OV-3) ovarian cells. A cell cycle study revealed lesser toxicity of nanomedicines towards normal cells and increased toxicity towards cancer cells. The IC50 values determined for dioxadet nanoformulations were in the range of 0.47−4.98 μg/mL for cancer cells, which is close to the free drug’s efficacy (2.60−4.14 μg/mL). The highest cytotoxic effect was found for dioxadet loaded to mPEG-b-PCL nanoparticles.
Collapse
|
3
|
Mikolaichuk OV, Popova EA, Protas AV, Rakipov IT, Nerukh DA, Petrov AV, Charykov NA, Ageev SV, Tochilnikov GV, Zmitrichenko IG, Stukov AN, Semenov KN, Sharoyko VV. A cytostatic drug from the class of triazine derivatives: Its properties in aqueous solutions, cytotoxicity, and therapeutic activity. J Mol Liq 2022. [DOI: 10.1016/j.molliq.2022.119043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Ma Y, Han J, Jiang J, Zheng Z, Tan Y, Liu C, Zhao Y. Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment. Life Sci 2020; 262:118565. [PMID: 33038371 DOI: 10.1016/j.lfs.2020.118565] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2020] [Revised: 09/30/2020] [Accepted: 10/01/2020] [Indexed: 12/18/2022]
Abstract
AIMS Anti-PD-L1 monoclonal antibody (mAb)-conjugated ultrasound (US) lipid-shelled microbubbles (PD-L1-MBs) were successfully synthesized to investigate whether that PD-L1-MBs could enhance anti-tumor effect in combination therapy with cisplatin (CDDP) under ultrasound mediation. MAIN METHODS Based on affinity between biotin and streptavidin, we prepared microbubbles conjugated with anti-PD-L1 mAb by membrane hydration and mechanical oscillation. A subcutaneous tumor model was established to test the anti-tumor effect and immunological activity of this combination therapy. Bax and Bcl-2 expression were detected by RT-qPCR and Immunohistochemistry. Cells undergoing apoptosis in tissue section were determined by TUNEL. Proliferation of splenocytes was analyzed by Flow cytometry. A cytotoxic T lymphocyte assay was performed by CTL. Expression of PD-L1 and CD8 in tissue section was examined by immunologfluorescence. Expression of IFN-γ, TNF-α, CD86 and CD80 was also detected by RT-qPCR. KEY FINDINGS We observed that the growth of the subcutaneous tumor was significantly slower in combined group than that in the group treated with either drug or microbubbles. Moreover, higher antitumor activity was observed in the combined group than that in cisplatin alone, which could be reflected by the number of apoptotic cells in tumor tissues and over expression of bax in the combined group. This combination treatment also exhibited a better immunological activity, increasing the infiltration of CD8+ T cells and the expression of several revelant cytokines. SIGNIFICANCE The ultrasound lipid-shelled PD-L1-MBs may enhance anti-tumor effects of cisplatin by blocking the PD-L1 site and improving immune function.
Collapse
Affiliation(s)
- Yao Ma
- Medical College of China Three Gorges University, Yichang, China; Department of Ultrasonography, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China
| | - Jiaxuan Han
- Medical College of China Three Gorges University, Yichang, China
| | - Jinjun Jiang
- Medical College of China Three Gorges University, Yichang, China
| | - Zhiwei Zheng
- Medical College of China Three Gorges University, Yichang, China
| | - Yandi Tan
- Medical College of China Three Gorges University, Yichang, China
| | - Chaoqi Liu
- Medical College of China Three Gorges University, Yichang, China; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, China.
| | - Yun Zhao
- Medical College of China Three Gorges University, Yichang, China.
| |
Collapse
|
5
|
Shahid M, Subhan F, Ahmad N, Sewell RDE. Efficacy of a topical gabapentin gel in a cisplatin paradigm of chemotherapy-induced peripheral neuropathy. BMC Pharmacol Toxicol 2019; 20:51. [PMID: 31462283 PMCID: PMC6714310 DOI: 10.1186/s40360-019-0329-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Accepted: 08/11/2019] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Chemotherapy induced peripheral neuropathy (CIPN) has been attributed to chemotherapeutic agents such as cisplatin which adversely affect disease outcome leading to increased cancer related morbidity. The clinical efficacy of systemic gabapentin in neuropathic pain management is limited by central side-effects in addition to a scarceness of conclusive evidence of its efficacy in CIPN management. The topical route therefore may provide a relatively safe alternative for neuropathic pain treatment in general and CIPN in particular. METHODS Cisplatin induced neuropathic nociception was established in rats after a single weekly cisplatin injection (3.0 mg/kg, intraperitoneally) for 4 weeks. The evoked neuropathic sensation of allodynia was assessed by plantar application of von Frey monofilaments as the paw withdrawal threshold (PWT), whereas the expression of heat-hypoalgesia was determined on a hot-plate as paw withdrawal latency (PWL). Gabapentin gel (10% w/w) was applied three-times daily on the hind paws while in a concurrent systemic study, gabapentin was administered daily (75 mg/kg, intraperitoneally) for 4 weeks. To assess any evidence of neurological adverse symptoms of cisplatin and the central side-effect propensity of systemic or topical gabapentin, evaluation of motor coordination (rotarod test) and gait (footprint analysis) were performed. RESULTS Cisplatin invoked a progressive development of neuropathic hind paw allodynia (decreased PWT, days 7-28) and heat hypoalgesia (increased PWL, days 21-28). Topical gabapentin significantly delayed the expression of both allodynia on protocol days 21 and 28 and heat-hypoalgesia (day 28). Systemic gabapentin displayed a comparative anti-neuropathic predisposition through a sustained suppression of tactile allodynia on days 14 and 21-28 as well as thermal hypoalgesia (days 21 and 28). Systemic gabapentin also impaired motor coordination and gait thus affirming its clinically documented central side effects, but these outcomes were not evident after topical treatment. CONCLUSIONS Both topical and systemic gabapentin exhibit a propensity to attenuate CIPN in a cisplatin paradigm. Gabapentin applied topically may therefore provide an adjunctive or alternative route for CIPN management upon cessation of systemic medications due to intolerable side-effects.
Collapse
Affiliation(s)
- Muhammad Shahid
- Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Pakistan
- Department of Pharmacy, University of Peshawar, Peshawar, 25120 Pakistan
| | - Fazal Subhan
- Department of Pharmacy, University of Peshawar, Peshawar, 25120 Pakistan
- Department of Pharmacy, CECOS University, Hayatabad, Phase 6, Peshawar, Khyber Pakhtunkhwa Pakistan
| | - Nisar Ahmad
- Department of Pharmacy, University of Peshawar, Peshawar, 25120 Pakistan
- Department of Pharmacy, Abasyn University, Peshawar, Pakistan
| | - Robert D. E. Sewell
- Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, CF10 3NU UK
| |
Collapse
|
6
|
Zhikhoreva AA, Belashov AV, Bespalov VG, Semenov AL, Semenova IV, Tochilnikov GV, Zhilinskaya NT, Vasyutinskii OS. Morphological changes in the ovarian carcinoma cells of Wistar rats induced by chemotherapy with cisplatin and dioxadet. BIOMEDICAL OPTICS EXPRESS 2018; 9:5817-5827. [PMID: 30460164 PMCID: PMC6238906 DOI: 10.1364/boe.9.005817] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 10/19/2018] [Accepted: 10/19/2018] [Indexed: 06/09/2023]
Abstract
The development of new express methods for the analysis of the efficacy of anti-cancer therapy on the cellular level is highly desirable for the analysis of chemotherapeutic agent performance. In this paper we suggest the use of parameters of cell morphology determined by holographic microscopy and tomography for the effective label free quantitative analysis of cell viability under antitumor chemotherapy and thus of cytostatic agent efficacy. As shown, measured phase shifts and cell morphology change dramatically as a result of chemotherapy and depend strongly on the cell type and agent applied. Experimentally, a comparative analysis of the antitumor efficacy of the two cytostatics, cisplatin and dioxadet, that are commonly used for chemotherapy of disseminated ovarian carcinoma has been performed. The experiments were carried out on the Wistar rat model. An essential difference in the morphology of cells, both normal (erythrocytes) and cancerous, present in ascitic fluid taken from the non-treated group of rats and the groups treated with either dioxadet or cisplatin, has been observed. The results obtained can be interpreted as an indication of the antitumor performance of both cytostatics at the cellular level and as a demonstration of the higher efficacy of therapy with dioxadet as compared to that with cisplatin. Differences in cell morphology are suggested to be applied as quantitative markers of cell viability and cytostatic agent efficacy. The conclusions made are supported by a comparison with the results of recent experiments based on survival rates of laboratory animals treated with these agents..
Collapse
Affiliation(s)
- A. A. Zhikhoreva
- Ioffe Institute; 26 Polytekhnicheskaya, St.Petersburg, 194021,
Russia
| | - A. V. Belashov
- Ioffe Institute; 26 Polytekhnicheskaya, St.Petersburg, 194021,
Russia
| | - V. G. Bespalov
- ITMO University; Kronverkskiy pr., 49, St. Petersburg, 197101,
Russia
- N. N. Petrov National Medical Research Center of Oncology, 68, Leningradskaya ul., Pesochnyi, St. Petersburg, 197758,
Russia
| | - A. L. Semenov
- N. N. Petrov National Medical Research Center of Oncology, 68, Leningradskaya ul., Pesochnyi, St. Petersburg, 197758,
Russia
| | - I. V. Semenova
- Ioffe Institute; 26 Polytekhnicheskaya, St.Petersburg, 194021,
Russia
| | - G. V. Tochilnikov
- N. N. Petrov National Medical Research Center of Oncology, 68, Leningradskaya ul., Pesochnyi, St. Petersburg, 197758,
Russia
| | - N. T. Zhilinskaya
- N. N. Petrov National Medical Research Center of Oncology, 68, Leningradskaya ul., Pesochnyi, St. Petersburg, 197758,
Russia
- Peter the Great St.Petersburg Polytechnic University; 29, Polytekhnicheskaya, St. Petersburg, 195251,
Russia
| | | |
Collapse
|
7
|
Cai QH, Tang Y, Fan SH, Zhang ZF, Li H, Huang SQ, Wu DM, Lu J, Zheng YL. In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38MAPK/NF-κB signaling pathway. Biomed Pharmacother 2017; 95:1830-1837. [PMID: 28968927 DOI: 10.1016/j.biopha.2017.09.086] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Revised: 09/14/2017] [Accepted: 09/18/2017] [Indexed: 02/08/2023] Open
Abstract
OBJECTIVES During this study, we aimed to analyze the correlation between dosages of dexmedetomidine (DEX) and the p38MAPK/NF-κB signaling pathway, and their effects on immune function and tumor growth in rats with ovarian cancer (OC). METHODS A total of 100 rats were selected for the purposes of the study. The normal group consisted of 20 rats, while the remaining 80 rats were utilized for OC model establishment purposes, and further assigned into the model, 0.2 DEX, 1 DEX and 5 DEX groups (based on respective dosages of DEX, n=20 per group). The tumor inhibition rate was calculated. Positive expressions of p38 and NF-κB in ovarian tissues were examined by means of immunohistochemical staining. Cell transformation as well as lymphocyte proliferation rates were measured using MTT. Cell cycle and apoptosis of CD4+ and CD8+ cells were determined by flow cytometry. Serum levels of IL-2 and TNF-α were detected using ELISA, while qRT-PCR and western blotting methods were used to analyze mRNA and protein expressions of p38 and NF-κB. RESULTS Compared with the normal group, the other four groups exhibited up-regulated IL-2, TNF-α serum levels as well as up regulated expressions of p38, NF-κB65 mRNA and protein; while the respective percentages of both CD4+ and CD8+ T cells exhibited down-regulated rates. The other four groups displayed increases in tumor weight and cell apoptosis, as well as decreased levels of cell proliferation and transformation rates. The aforementioned findings of the study ultimately highlighted a greater tendency among the three DEX groups in comparison to the model group. CONCLUSION The findings of the study suggest that a particular dosage of DEX may act to enhance the immune function of rats with OC by inhibiting the p38MAPK/NF-κB signaling pathway.
Collapse
Affiliation(s)
- Qi-Hang Cai
- Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou 221116, PR China
| | - Yao Tang
- Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou 221116, PR China
| | - Shao-Hua Fan
- Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou 221116, PR China
| | - Zi-Feng Zhang
- Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou 221116, PR China
| | - Hong Li
- Department of Anesthesiology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200090, PR China
| | - Shao-Qiang Huang
- Department of Anesthesiology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200090, PR China
| | - Dong-Mei Wu
- Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou 221116, PR China.
| | - Jun Lu
- Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou 221116, PR China.
| | - Yuan-Lin Zheng
- Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou 221116, PR China.
| |
Collapse
|
8
|
Bespalov VG, Alvovsky IK, Tochilnikov GV, Stukov AN, Vyshinskaya EA, Semenov AL, Vasilyeva IN, Belyaeva OA, Kireeva GS, Senchik KY, Zhilinskaya NT, Von JD, Krasilnikova LA, Alexandrov VA, Khromov-Borisov NN, Baranenko DA, Belyaev AM. Comparative efficacy evaluation of catheter intraperitoneal chemotherapy, normothermic and hyperthermic chemoperfusion in a rat model of ascitic ovarian cancer. Int J Hyperthermia 2017; 34:545-550. [PMID: 28893108 DOI: 10.1080/02656736.2017.1375161] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
OBJECTIVES The choice of an optimal administration route for intraperitoneal (IP) chemotherapy and a suitable chemotherapeutic regime in the treatment of ovarian cancer remains a controversy. We investigated survival outcomes according to catheter intraperitoneal chemotherapy (CIPC), normothermic and hyperthermic chemoperfusion (NIPEC and HIPEC) with cytostatic drugs dioxadet and cisplatin in rats with transplantable ascitic ovarian cancer. METHODS Ascitic liquid containing 1 × 107 tumour cells was inoculated to female Wistar rats and 48 hours after rats received dioxadet and cisplatin at the maximum tolerated doses. Dioxadet at doses 1.5, 30 and 15 mg/kg and cisplatin at doses 4, 40 and 20 mg/kg body weight were administered for CIPC, NIPEC and HIPEC, respectively. Rats in the control groups received physiological saline and CIPC with physiological saline was regarded as the untreated control. The antitumor activity of the drugs was evaluated as an increase in average life expectancy (ALE). Analysis of the data was based primarily on Bayesian statistics and included Kaplan-Meier method, log-rank test and hazard ratio (HR) estimation. RESULTS Compared to the untreated control CIPC, NIPEC and HIPEC with dioxadet significantly increased ALE by 101316, 61524 and 1.71735 days, whereas with cisplatin by 61013, 122437 and -13523 days, respectively. CONCLUSIONS Dioxadet and cisplatin show similar efficacy in the CIPC route. Compared with CIPC IP chemotherapy by chemoperfusions is more effective for both the drugs. Dioxadet in HIPEC showed highest survival benefit whereas largest effect during NIPEC is achieved with cisplatin.
Collapse
Affiliation(s)
- Vladimir G Bespalov
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia.,b International Research Centre "Biotechnologies of the Third Millennium", ITMO University , St. Petersburg , Russia
| | - Ivan K Alvovsky
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia.,b International Research Centre "Biotechnologies of the Third Millennium", ITMO University , St. Petersburg , Russia
| | - Grigory V Tochilnikov
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia.,b International Research Centre "Biotechnologies of the Third Millennium", ITMO University , St. Petersburg , Russia
| | - Alexandr N Stukov
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia
| | - Ekaterina A Vyshinskaya
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia
| | - Alexandr L Semenov
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia.,b International Research Centre "Biotechnologies of the Third Millennium", ITMO University , St. Petersburg , Russia
| | - Irina N Vasilyeva
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia.,b International Research Centre "Biotechnologies of the Third Millennium", ITMO University , St. Petersburg , Russia
| | - Olesya A Belyaeva
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia
| | - Galina S Kireeva
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia
| | - Konstantin Y Senchik
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia
| | - Nadezhda T Zhilinskaya
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia
| | - Julia D Von
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia
| | - Larisa A Krasilnikova
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia
| | - Valery A Alexandrov
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia.,b International Research Centre "Biotechnologies of the Third Millennium", ITMO University , St. Petersburg , Russia
| | - Nikita N Khromov-Borisov
- c Scientific Council, R.R. Vreden Russian Scientific Research Institute of Traumatology and Orthopedics , St. Petersburg , Russia
| | - Denis A Baranenko
- b International Research Centre "Biotechnologies of the Third Millennium", ITMO University , St. Petersburg , Russia
| | - Alexey M Belyaev
- a Scientific Laboratory of Cancer Chemoprevention and Oncopharmacology , N.N. Petrov Research Institute of Oncology , St. Petersburg , Russia
| |
Collapse
|